We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -1.13% | 8.75 | 8.50 | 9.00 | 8.85 | 8.75 | 8.85 | 309,158 | 13:20:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.37 | 15.23M |
TIDMSBTX
RNS Number : 7397V
SkinBioTherapeutics PLC
06 December 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Posting of Annual Report and AGM Notice
6 December 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health confirms that the Notice of Annual General Meeting ("AGM"), form of proxy and Annual Report and Accounts for the year ended 30 June 2023 have been posted to shareholders.
An electronic copy of the Annual Report and Accounts and the Notice of AGM are also available on the Company's website - www.skinbiotherapeutics.com/investor-relations .
The AGM will be held at 9:00am on Friday 29 December 2023 at The Clarion Hotel, Witney Way, Boldon, NE35 9PE.
-Ends-
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191 495 7325 Stuart J. Ashman, CEO Manprit Randhawa, CFO Cavendish Capital Markets Limited Tel: +44 (0) 20 7220 0500 (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales) Instinctif Partners (financial press) Tel: +44 (0) 20 7457 2020 Melanie Toyne-Sewell / Jack Kincade SkinBioTherapeutics@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R) , is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps(TM), a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit : www.skinbiotherapeutics.com and www.axisbiotix.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NOAUVVRROWUURAA
(END) Dow Jones Newswires
December 06, 2023 02:00 ET (07:00 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions